The MIgGRATE Study is evaluating an investigational immunoglobulin G (IgG) drug called TAK-881 as a potential treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). TAK-881 is a subcutaneous IgG treatment with a higher IgG concentration than HYQVIA®, which will allow for a smaller amount of the IgG Treatment to be administered under the skin. TAK-881 has the potential to reduce infusion side effects with intravenous infusions and reduce the number of infusion sites and/or length of infusion experienced, with the hope of achieving a better infusion experience.
Who can participate in this study?
You may qualify to participate in this study if you are at least 18 years of age and you:
- Have been diagnosed with CIDP, or possible CIDP
- Have responded to IgG treatment in the past
- Have been receiving the same IgG treatment for 12 weeks
You will also need to meet additional criteria, which the study doctor and staff will explain.
What will happen?
This study will include:
- Subcutaneous (under the skin) study drug infusions every 3 or 4 weeks
- Frequent visits with the study doctor and staff
- Up to 4 years of study participation
Study drug infusions and study visits will be provided at no cost to you. You may also be reimbursed for pre-approved
expenses related to your study participation.
For more information on this study, please visit The MIgGrate Study
Spotlight
